Advertisement
Advertisement
VRTX
Vertex Pharmaceuticals Inc
503.07
USDSponsored
-1.66
-0.33%
Oct 05, 11:58 UTC -4
Open
VRTX Earnings Reports
Positive Surprise Ratio
VRTX beat 31 of 42 last estimates.
74%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$3.48B
/$4.89
Implied change from Q2 26 (Revenue/ EPS)
+4.30%
/+3.38%
Implied change from Q3 25 (Revenue/ EPS)
+13.03%
/+1.88%
Vertex Pharmaceuticals Inc earnings per share and revenue
On Aug 03, 2026, VRTX reported earnings of 4.73 USD per share (EPS) for Q2 26, missing the estimate of 4.83 USD, resulting in a -2.11% surprise. Revenue reached 3.33 billion, compared to an expected 3.30 billion, with a 1.07% difference. The market reacted with a +1.70% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 15 analysts forecast an EPS of 4.89 USD, with revenue projected to reach 3.48 billion USD, implying an increase of 3.38% EPS, and increase of 4.30% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$0.07
Surprise
+2,158.06%
Nanobiotix S.A. - ADR
Report Date
Sep 25, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.70
Surprise
-496.76%
Inventiva S.A. - ADR
Report Date
Sep 28, 2026 For Q2 26
Estimate
-$0.37
Actual
-$0.25
Surprise
+33.55%
Rezolute, Inc. Common Stock (NV)
Report Date
Sep 24, 2026 For Q4 26
Estimate
-$0.15
Actual
-$0.20
Surprise
-32.45%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
$0.00
Surprise
+99.70%
Palatin Technologies, Inc. Common Stock
Report Date
Sep 28, 2026 For Q4 26
Estimate
-$1.21
Actual
-$1.11
Surprise
+8.42%
NeuroSense Therapeutics Ltd. Ordinary Shares
Report Date
Sep 25, 2026 For Q2 26
Estimate
-$3.26
Actual
-$2.10
Surprise
+35.66%
FAQ
What were Vertex Pharmaceuticals Inc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Vertex Pharmaceuticals Inc reported EPS of $4.73, missing estimates by -2.11%, and revenue of $3.33B, 1.07% above expectations.
How did the market react to Vertex Pharmaceuticals Inc's Q2 2026 earnings?
The stock price moved up 1.7%, changed from $470.72 before the earnings release to $478.70 the day after.
When is Vertex Pharmaceuticals Inc expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for Vertex Pharmaceuticals Inc's next earnings report?
Based on 15
analysts, Vertex Pharmaceuticals Inc is expected to report EPS of $4.89 and revenue of $3.48B for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.